Document is current
Any future updates will be listed below
-
Authors
Feleus, Stephanie https://orcid.org/0000-0002-1160-0920
Vo, Mai-Ly T. D. https://orcid.org/0009-0005-5028-4288
Kuijper, Laura C. M. https://orcid.org/0009-0008-6084-8317
Roos, Raymund A. C. https://orcid.org/0000-0001-5591-1133
de Bot, Susanne T. https://orcid.org/0000-0002-3512-2468
-
Funding
Funding for this research was provided by:
private Huntington's Disease community donations
- License Information
-
More Information
Article History
Received: 7 May 2024
Revised: 4 November 2024
Accepted: 17 November 2024
First Online: 12 December 2024
Declarations
:
: This research was supported by private HD community donations. We received no funding from commercial or not-for-profit parties. HD-MED is an investigator-initiated study set up by the Department of Neurology and Department of Clinical Pharmacy and Toxicology of the Leiden University Medical Center. The authors declare that there are no conflicts of interest relevant to this work.
: All participants in the HD-MED and ENROLL-HD study gave written informed consent to participate in the study and have their data published in international journals. The HD-MED study is approved by the medical research ethics committee Leiden Den Haag Delft under number NL70391.058.19 and is registered in the International Clinical Trials Registry Platform under number NL-OMON55123. The HD-med study is in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All sites participating in the ENROLL-HD study have obtained local ethical approval. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
